Shopping Cart 0
Cart Subtotal
AED 0

Glioblastoma Multiforme (GBM): Opportunity Analysis and Forecasts to 2027

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
AED 40352

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
AED 80703

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
AED 121055

Details

Glioblastoma Multiforme (GBM): Opportunity Analysis and Forecasts to 2027

Summary

Glioblastoma multiforme (GBM), otherwise known as Grade IV astrocytoma, is the most aggressive form of brain cancer and characterized as a disease with one of the highest unmet needs in oncology, with patients having a median overall survival (OS) between one and two years. The lack of approved therapies is mainly due to the inability of drugs to penetrate the blood-brain barrier (BBB). The only targeted agent approved for recurrent GBM patients is Roche's Avastin (bevacizumab), approved in the US in 2008 and Japan in 2013 and used off-label in the 5EU and China. Otherwise, generic temozolomide in combination with radiotherapy makes up the majority of the GBM market and is considered the standard of care across the 8MM.

The GBM market is expected to experience modest growth in the 8MM (US, France, Germany, Italy, Spain, the UK, Japan, and urban China) from 2017-2027. This is driven by the launch of nine late-stage agents, primarily immunotherapies and small-molecules that can bypass the limitations of the BBB, which are expected to launch at premium-prices. In recent years, many late-stage agents were discontinued due to multiple factors. Developers will need to be astute in terms of their clinical development of novel therapies in order to secure approvals. Despite this, a myriad of opportunities remain in the GBM space with room for innovative therapies that are more efficacious than the current standard of care (SOC).

Key Questions Answered

- Which pipeline agents are the most promising and expected to launch in the 8MM? What are the forecast sales of these agents and what will be their impact in the GBM market?

- What are the main unmet needs in GBM, which pipeline drugs will fulfill these needs, and to what extent?

- What are the current research and development (R&D) strategies being explored and how can developers incorporate these methods into their business strategy?

- Key Opinions Leader (KOL) insights across the 8MM, relating to the current treatment options and opinions on the late- and early-stage pipeline agents.

Scope

- Overview of GBM, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management.

- Annualized GBM therapeutics market revenue, cost of therapy per patient, and treatment usage patterns in eight geographic regions, forecast from 2017 to 2027.

- Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the GBM therapeutics market.

- Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for GBM. The most promising candidates in late-stage development are profiled.

- Analysis of the current and future market competition in the global GBM market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

The report will enable you to-

- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.

- Develop business strategies by understanding the trends shaping and driving the global GBM market.

- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global GBM market in the future.

- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

READ MORE

Table Of Content

Scope

1 Table of Contents

1 Table of Contents 2

1.1 List of Tables 5

1.2 List of Figures 5

2 Executive Summary 6

2.1 New Entrants Will Drive Modest Growth Across the 8MM from 2017 to 2027 6

2.2 Launch of Immunotherapies and Biomarker-Driven Therapies Will Lead to Change in the GBM Landscape 8

2.3 High Unmet Needs Exist in the GBM Market, Especially in Patients Refractory to Avastin 9

2.4 Pipeline Agents Will Offer Incremental Improvements over Current Therapies 10

2.5 What Do Physicians Think? 12

3 Introduction 15

3.1 Catalyst 15

3.2 Related Reports 15

3.3 Upcoming Related Reports 16

4 Disease Overview 17

4.1 Etiology and Pathophysiology 17

4.1.1 Etiology 17

4.1.2 Pathophysiology 17

4.2 Symptoms 19

5 Epidemiology 21

5.1 Disease Background 21

5.2 Risk Factors and Comorbidities 22

5.3 Global and Historical Trends 23

5.4 Forecast Methodology 24

5.4.1 Sources 25

5.4.2 Forecast Assumptions and Methods 27

5.5 Epidemiological Forecast for Brain Cancer (2017-2027) 32

5.5.1 Diagnosed Incident Cases of Brain Cancer 32

5.5.2 Age-Specific Diagnosed Incident Cases of Brain Cancer 33

5.5.3 Sex-Specific Diagnosed Incident Cases of Brain Cancer 34

5.5.4 Five-Year Diagnosed Prevalent Cases of Brain Cancer 35

5.5.5 Diagnosed Incident Cases of Brain Cancer by Type 37

5.6 Discussion 38

5.6.1 Epidemiological Forecast Insight 38

5.6.2 Limitations of the Analysis 39

5.6.3 Strengths of the Analysis 39

6 Current Treatment Options 40

6.1 Overview 40

7 Unmet Needs Assessment and Opportunity Analysis 43

7.1 Overview 43

7.2 Identification of New Treatment Options for Patients with rGBM Refractory to Avastin 44

7.3 More Efficacious Treatment for Patients with MGMT-Unmethylated Promoters 46

7.4 Criteria to Evaluate Tumor Response 47

7.5 Reduced Use of Steroids in GBM Patients 48

7.6 Identification of Biomarkers Predictive of Therapeutic Efficacy 49

7.7 More Agents Required for Unresectable GBM 50

8 R&D Strategies 53

8.1 Overview 53

8.1.1 Assessment of Immunotherapy Efficacy in GBM 54

8.1.2 Increased Use of Biomarkers to Better Predict Treatment Efficacy 56

8.1.3 Moving Towards Less-Cumbersome Cancer Vaccines to Facilitate Approval 57

8.1.4 Local Administration of Therapeutics During Surgery 59

8.1.5 Revisiting Older Strategies and Developing Modifications to Increase Effectiveness 60

8.2 Clinical Trial Design 61

8.2.1 Clinical Endpoints 62

8.2.2 Comparator Arms 67

8.2.3 Combination Approach 67

9 Pipeline Assessment 70

9.1 Overview 70

9.2 Recent Drug Failures in GBM 74

9.3 Innovative Early-Stage Approaches 74

9.3.1 Checkpoint Modulator Combinations 76

9.3.2 Vaccines and T-cell Therapies 77

9.3.3 Small Molecules 78

10 Pipeline Valuation Analysis 80

10.1 Clinical Benchmark of Key Pipeline Drugs 81

10.2 Commercial Benchmark of Key Pipeline Drugs 84

10.3 Competitive Assessment 87

10.4 Top Line 10-Year Forecast 89

10.4.1 US 94

10.4.2 5EU 94

10.4.3 Japan 95

10.4.4 China (Urban) 96

11 Appendix 97

11.1 Bibliography 97

11.2 Abbreviations 104

11.3 Methodology 107

11.4 Forecasting Methodology 107

11.4.1 Diagnosed GBM Patients 108

11.4.2 Percent Drug-Treated Patients 108

11.4.3 Drugs Included in Each Therapeutic Class 108

11.4.4 Launch and Patent Expiry Dates 109

11.4.5 General Pricing Assumptions 109

11.4.6 General Forecast Assumptions 111

11.4.7 Individual Drug Assumptions 112

11.4.8 Generic and Biosimilar Erosion 114

11.4.9 Pricing of Pipeline Agents 114

11.5 Physicians and Specialists Included in this Study 117

11.5.1 High-Prescribing Physician Survey 120

11.6 About the Authors 121

11.6.1 Author 121

11.6.2 Epidemiologist 121

11.6.3 Therapy Director 121

11.6.4 Global Director of Therapy Analysis and Epidemiology 122

11.6.5 Global Head of Healthcare 123

11.7 About GlobalData 124

11.8 Contact Us 124

11.9 Disclaimer 124


List Of Figure

1.2 List of Figures

Figure 1: GBM Sales by Country, 2017-2027 8

Figure 2: Competitive Assessment of Late-Stage Pipeline Agents in Newly Diagnosed GBM, 2017-2027 11

Figure 3: Competitive Assessment of Late-Stage Pipeline Agents in Recurrent GBM, 2017-2027 12

Figure 4: 8MM, Age-Standardized Diagnosed Incidence of Brain Cancer, Men and Women, All Ages, 2017 24

Figure 5: Sources Used and Not Used to Forecast Diagnosed Incident Cases of Brain Cancer 25

Figure 6: Sources Used and Not Used to Forecast the Five-Year Diagnosed Prevalent Cases of Brain Cancer 26

Figure 7: Sources Used to Forecast Diagnosed Incident Cases of Brain Cancer by Type 27

Figure 8: 8MM, Diagnosed Incident Cases of Brain Cancer, Men and Women, All Ages, 2017 32

Figure 9: 8MM, Age-Specific Diagnosed Incident Cases of Brain Cancer, Men and Women, 2017, N 33

Figure 10: 8MM, Sex-Specific Diagnosed Incident Cases of Brain Cancer, Men and Women, All Ages, 2017 34

Figure 11: 8MM, Five-Year Diagnosed Prevalent Cases of Brain Cancer, Men and Women, All Ages, 2017 36

Figure 12: 8MM, Diagnosed Incident Cases of Brain Cancer by Type, Men and Women, All Ages, 2017, N 37

Figure 13: Unmet Needs and Opportunities in GBM 44

Figure 14: Overview of the Development Pipeline in GBM 72

Figure 15: Late-Stage Therapies for GBM, 2018 73

Figure 16: Competitive Assessment of Late-Stage Pipeline Agents in Newly Diagnosed GBM, 2017-2027 88

Figure 17: Competitive Assessment of Late-Stage Pipeline Agents in Recurrent GBM, 2017-2027 89

Figure 18: GBM Sales by Country, 2017-2027 91

Figure 19: GBM Sales by Therapeutic Class, 2017-2027 92


List Of Table

1.1 List of Tables

Table 1: Glioblastoma: Key Metrics in Eight Major Pharmaceutical Markets, 2017-2027 6

Table 2: Symptoms of Glioblastoma 20

Table 3: Description of Brain Cancer Types 22

Table 4: Leading Treatments for GBM 42

Table 5: Treatment Guidelines for GBM 42

Table 6: Design of Current Phase III Trials in GBM 66

Table 7: Glioblastoma-Late Stage Pipeline, 2018 73

Table 8: GBM-Recent late-stage drug discontinuations 74

Table 9: Innovative Early-Stage Approaches for GBM, 2018 75

Table 10 Clinical Benchmark of Key Marketed and Pipeline Drugs-Newly Diagnosed GBM 81

Table 11: Clinical Benchmark of Key Marketed and Pipeline Drugs-Recurrent GBM 82

Table 12: Commercial Benchmark of Key Marketed and Pipeline Drugs-Newly Diagnosed GBM 84

Table 13: Commercial Benchmark of Key Marketed and Pipeline Drugs-Recurrent GBM 85

Table 14: Key Events Impacting Sales for Glioblastoma, 2017-2027 93

Table 15: GBM Market-Drivers and Barriers, 2017-2027 93

Table 16: Key Launch Dates in the GBM Market, 20172027 109

Table 17: Key Patent Expiries in the GBM Market, 2017-2027 109

Table 18: Average Body Weight and Surface Area Across the 8MM 111

Table 19: High-Prescribing Physicians (non-KOLs) Surveyed, By Country 120

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies


Companies

Roche

Merck

Bristol-Myers Squibb

AbbVie

Celgene.

Eisai

Arbor Pharmaceutical

Northwest Biotherapeutics

Chugai Pharmaceutical

Ono Pharmaceutical

Tocagen

DelMar Pharmaceuticals

Diffusion Pharmaceuticals

DNAtrix

Company Profile

Company Profile Title

Glioblastoma Multiforme (GBM): Opportunity Analysis and Forecasts to 2027

Summary

Glioblastoma multiforme (GBM), otherwise known as Grade IV astrocytoma, is the most aggressive form of brain cancer and characterized as a disease with one of the highest unmet needs in oncology, with patients having a median overall survival (OS) between one and two years. The lack of approved therapies is mainly due to the inability of drugs to penetrate the blood-brain barrier (BBB). The only targeted agent approved for recurrent GBM patients is Roche's Avastin (bevacizumab), approved in the US in 2008 and Japan in 2013 and used off-label in the 5EU and China. Otherwise, generic temozolomide in combination with radiotherapy makes up the majority of the GBM market and is considered the standard of care across the 8MM.

The GBM market is expected to experience modest growth in the 8MM (US, France, Germany, Italy, Spain, the UK, Japan, and urban China) from 2017-2027. This is driven by the launch of nine late-stage agents, primarily immunotherapies and small-molecules that can bypass the limitations of the BBB, which are expected to launch at premium-prices. In recent years, many late-stage agents were discontinued due to multiple factors. Developers will need to be astute in terms of their clinical development of novel therapies in order to secure approvals. Despite this, a myriad of opportunities remain in the GBM space with room for innovative therapies that are more efficacious than the current standard of care (SOC).

Key Questions Answered

- Which pipeline agents are the most promising and expected to launch in the 8MM? What are the forecast sales of these agents and what will be their impact in the GBM market?

- What are the main unmet needs in GBM, which pipeline drugs will fulfill these needs, and to what extent?

- What are the current research and development (R&D) strategies being explored and how can developers incorporate these methods into their business strategy?

- Key Opinions Leader (KOL) insights across the 8MM, relating to the current treatment options and opinions on the late- and early-stage pipeline agents.

Scope

- Overview of GBM, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management.

- Annualized GBM therapeutics market revenue, cost of therapy per patient, and treatment usage patterns in eight geographic regions, forecast from 2017 to 2027.

- Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the GBM therapeutics market.

- Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for GBM. The most promising candidates in late-stage development are profiled.

- Analysis of the current and future market competition in the global GBM market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

The report will enable you to-

- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.

- Develop business strategies by understanding the trends shaping and driving the global GBM market.

- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global GBM market in the future.

- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

READ MORE

Scope

1 Table of Contents

1 Table of Contents 2

1.1 List of Tables 5

1.2 List of Figures 5

2 Executive Summary 6

2.1 New Entrants Will Drive Modest Growth Across the 8MM from 2017 to 2027 6

2.2 Launch of Immunotherapies and Biomarker-Driven Therapies Will Lead to Change in the GBM Landscape 8

2.3 High Unmet Needs Exist in the GBM Market, Especially in Patients Refractory to Avastin 9

2.4 Pipeline Agents Will Offer Incremental Improvements over Current Therapies 10

2.5 What Do Physicians Think? 12

3 Introduction 15

3.1 Catalyst 15

3.2 Related Reports 15

3.3 Upcoming Related Reports 16

4 Disease Overview 17

4.1 Etiology and Pathophysiology 17

4.1.1 Etiology 17

4.1.2 Pathophysiology 17

4.2 Symptoms 19

5 Epidemiology 21

5.1 Disease Background 21

5.2 Risk Factors and Comorbidities 22

5.3 Global and Historical Trends 23

5.4 Forecast Methodology 24

5.4.1 Sources 25

5.4.2 Forecast Assumptions and Methods 27

5.5 Epidemiological Forecast for Brain Cancer (2017-2027) 32

5.5.1 Diagnosed Incident Cases of Brain Cancer 32

5.5.2 Age-Specific Diagnosed Incident Cases of Brain Cancer 33

5.5.3 Sex-Specific Diagnosed Incident Cases of Brain Cancer 34

5.5.4 Five-Year Diagnosed Prevalent Cases of Brain Cancer 35

5.5.5 Diagnosed Incident Cases of Brain Cancer by Type 37

5.6 Discussion 38

5.6.1 Epidemiological Forecast Insight 38

5.6.2 Limitations of the Analysis 39

5.6.3 Strengths of the Analysis 39

6 Current Treatment Options 40

6.1 Overview 40

7 Unmet Needs Assessment and Opportunity Analysis 43

7.1 Overview 43

7.2 Identification of New Treatment Options for Patients with rGBM Refractory to Avastin 44

7.3 More Efficacious Treatment for Patients with MGMT-Unmethylated Promoters 46

7.4 Criteria to Evaluate Tumor Response 47

7.5 Reduced Use of Steroids in GBM Patients 48

7.6 Identification of Biomarkers Predictive of Therapeutic Efficacy 49

7.7 More Agents Required for Unresectable GBM 50

8 R&D Strategies 53

8.1 Overview 53

8.1.1 Assessment of Immunotherapy Efficacy in GBM 54

8.1.2 Increased Use of Biomarkers to Better Predict Treatment Efficacy 56

8.1.3 Moving Towards Less-Cumbersome Cancer Vaccines to Facilitate Approval 57

8.1.4 Local Administration of Therapeutics During Surgery 59

8.1.5 Revisiting Older Strategies and Developing Modifications to Increase Effectiveness 60

8.2 Clinical Trial Design 61

8.2.1 Clinical Endpoints 62

8.2.2 Comparator Arms 67

8.2.3 Combination Approach 67

9 Pipeline Assessment 70

9.1 Overview 70

9.2 Recent Drug Failures in GBM 74

9.3 Innovative Early-Stage Approaches 74

9.3.1 Checkpoint Modulator Combinations 76

9.3.2 Vaccines and T-cell Therapies 77

9.3.3 Small Molecules 78

10 Pipeline Valuation Analysis 80

10.1 Clinical Benchmark of Key Pipeline Drugs 81

10.2 Commercial Benchmark of Key Pipeline Drugs 84

10.3 Competitive Assessment 87

10.4 Top Line 10-Year Forecast 89

10.4.1 US 94

10.4.2 5EU 94

10.4.3 Japan 95

10.4.4 China (Urban) 96

11 Appendix 97

11.1 Bibliography 97

11.2 Abbreviations 104

11.3 Methodology 107

11.4 Forecasting Methodology 107

11.4.1 Diagnosed GBM Patients 108

11.4.2 Percent Drug-Treated Patients 108

11.4.3 Drugs Included in Each Therapeutic Class 108

11.4.4 Launch and Patent Expiry Dates 109

11.4.5 General Pricing Assumptions 109

11.4.6 General Forecast Assumptions 111

11.4.7 Individual Drug Assumptions 112

11.4.8 Generic and Biosimilar Erosion 114

11.4.9 Pricing of Pipeline Agents 114

11.5 Physicians and Specialists Included in this Study 117

11.5.1 High-Prescribing Physician Survey 120

11.6 About the Authors 121

11.6.1 Author 121

11.6.2 Epidemiologist 121

11.6.3 Therapy Director 121

11.6.4 Global Director of Therapy Analysis and Epidemiology 122

11.6.5 Global Head of Healthcare 123

11.7 About GlobalData 124

11.8 Contact Us 124

11.9 Disclaimer 124


List Of Figure

1.2 List of Figures

Figure 1: GBM Sales by Country, 2017-2027 8

Figure 2: Competitive Assessment of Late-Stage Pipeline Agents in Newly Diagnosed GBM, 2017-2027 11

Figure 3: Competitive Assessment of Late-Stage Pipeline Agents in Recurrent GBM, 2017-2027 12

Figure 4: 8MM, Age-Standardized Diagnosed Incidence of Brain Cancer, Men and Women, All Ages, 2017 24

Figure 5: Sources Used and Not Used to Forecast Diagnosed Incident Cases of Brain Cancer 25

Figure 6: Sources Used and Not Used to Forecast the Five-Year Diagnosed Prevalent Cases of Brain Cancer 26

Figure 7: Sources Used to Forecast Diagnosed Incident Cases of Brain Cancer by Type 27

Figure 8: 8MM, Diagnosed Incident Cases of Brain Cancer, Men and Women, All Ages, 2017 32

Figure 9: 8MM, Age-Specific Diagnosed Incident Cases of Brain Cancer, Men and Women, 2017, N 33

Figure 10: 8MM, Sex-Specific Diagnosed Incident Cases of Brain Cancer, Men and Women, All Ages, 2017 34

Figure 11: 8MM, Five-Year Diagnosed Prevalent Cases of Brain Cancer, Men and Women, All Ages, 2017 36

Figure 12: 8MM, Diagnosed Incident Cases of Brain Cancer by Type, Men and Women, All Ages, 2017, N 37

Figure 13: Unmet Needs and Opportunities in GBM 44

Figure 14: Overview of the Development Pipeline in GBM 72

Figure 15: Late-Stage Therapies for GBM, 2018 73

Figure 16: Competitive Assessment of Late-Stage Pipeline Agents in Newly Diagnosed GBM, 2017-2027 88

Figure 17: Competitive Assessment of Late-Stage Pipeline Agents in Recurrent GBM, 2017-2027 89

Figure 18: GBM Sales by Country, 2017-2027 91

Figure 19: GBM Sales by Therapeutic Class, 2017-2027 92


List Of Table

1.1 List of Tables

Table 1: Glioblastoma: Key Metrics in Eight Major Pharmaceutical Markets, 2017-2027 6

Table 2: Symptoms of Glioblastoma 20

Table 3: Description of Brain Cancer Types 22

Table 4: Leading Treatments for GBM 42

Table 5: Treatment Guidelines for GBM 42

Table 6: Design of Current Phase III Trials in GBM 66

Table 7: Glioblastoma-Late Stage Pipeline, 2018 73

Table 8: GBM-Recent late-stage drug discontinuations 74

Table 9: Innovative Early-Stage Approaches for GBM, 2018 75

Table 10 Clinical Benchmark of Key Marketed and Pipeline Drugs-Newly Diagnosed GBM 81

Table 11: Clinical Benchmark of Key Marketed and Pipeline Drugs-Recurrent GBM 82

Table 12: Commercial Benchmark of Key Marketed and Pipeline Drugs-Newly Diagnosed GBM 84

Table 13: Commercial Benchmark of Key Marketed and Pipeline Drugs-Recurrent GBM 85

Table 14: Key Events Impacting Sales for Glioblastoma, 2017-2027 93

Table 15: GBM Market-Drivers and Barriers, 2017-2027 93

Table 16: Key Launch Dates in the GBM Market, 20172027 109

Table 17: Key Patent Expiries in the GBM Market, 2017-2027 109

Table 18: Average Body Weight and Surface Area Across the 8MM 111

Table 19: High-Prescribing Physicians (non-KOLs) Surveyed, By Country 120

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS


Companies

Roche

Merck

Bristol-Myers Squibb

AbbVie

Celgene.

Eisai

Arbor Pharmaceutical

Northwest Biotherapeutics

Chugai Pharmaceutical

Ono Pharmaceutical

Tocagen

DelMar Pharmaceuticals

Diffusion Pharmaceuticals

DNAtrix